Accelerated Hyperfractionated Radiotherapy in Supratentorial Malignant Astrocytomas

Basit Öğe Kaydı
dc.contributor.authorGenç, Mine
dc.contributor.authorZorlu, Abdullah Faruk
dc.contributor.authorAtahan, İbtisam Lale
dc.date.accessioned2020-03-26T16:36:11Z
dc.date.available2020-03-26T16:36:11Z
dc.date.issued2000
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: To determine the safety and effectiveness of accelerated hyperfractionated radiotherapy in the treatment of supratentorial malignant astrocytomas. Materials and methods: Between June 1995-July 1997, 75 patients were enrolled to a prospective phase II study. A total dose of 60 Gy was delivered in 2 Gy b.i.d. fractions with an interval of 6-8 h, 5 days per week, in an overall time of 3 weeks. The treatment protocol was planned to give 40 Gy to a treatment volume covering the contrast-enhancing lesion and oedema (+ 3-cm margin) and additional 20 Gy to the volume encompassing the contrast-enhancing lesion alone with a I-cm margin based on preoperative magnetic resonance imaging and/or CT findings. The patients had a median age of 46 years and a median Karnofsky performance status score of 80, Histology consisted of anaplastic astrocytoma (AA) in 16 (21%) and glioblastoma multiforme (GBM) in 59 (79%) patients. Results: Median survival was 11 months for all patients; 10 months for GEM patients and 40 months for AA patients. Survival rates at 1 and 3 years were 41%, 11% for all patients; 62, 37% for AA patients and 35, 6% for GEM patients, respectively. Multivariate analysis revealed significant impact of age, histology and neurological functional class on survival. The incidence of grade 3 or worse late neurological toxicity was 5.3%. Conclusions: Although accelerated hyperfractionated radiotherapy showed no significant advantage on survival, it shortened the treatment period from 6 to 3 weeks. Radiotherapy was well tolerated and the incidence of late toxicity is acceptable.en_US
dc.identifier.citationGenç, M., Zorlu, A. F., Atahan, İ. L., (2000). Accelerated Hyperfractionated Radiotherapy in Supratentorial Malignant Astrocytomas. Radiotherapy and Oncology, 56(2), 233-238. Doi: 10.1016/S0167-8140(00)00198-5
dc.identifier.doi10.1016/S0167-8140(00)00198-5en_US
dc.identifier.endpage238en_US
dc.identifier.issn0167-8140en_US
dc.identifier.issue2en_US
dc.identifier.pmid10927143en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage233en_US
dc.identifier.urihttps://dx.doi.org/10.1016/S0167-8140(00)00198-5
dc.identifier.urihttps://hdl.handle.net/20.500.12395/17180
dc.identifier.volume56en_US
dc.identifier.wosWOS:000088964700012en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorGenç, Mine
dc.language.isoenen_US
dc.publisherElsevier Sci Ireland Ltden_US
dc.relation.ispartofRadiotherapy and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectradiotherapyen_US
dc.subjectmalignant astrocytomaen_US
dc.subjectglioblastoma multiformeen_US
dc.subjectaccelerated hyperfractionateden_US
dc.subjectsupratentorialen_US
dc.titleAccelerated Hyperfractionated Radiotherapy in Supratentorial Malignant Astrocytomasen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
7180.pdf
Boyut:
94.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Radyasyon Onkolojisi/Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu